Sarepta Therapeutics Inc.

Core Business

Sarepta Therapeutics is the global leader in gene therapy and RNA-targeted therapeutics for rare neuromuscular diseases, generating $1.86 billion in net product revenue during 2025. Its Duchenne muscular dystrophy (DMD) gene therapy ELEVIDYS achieved $899 million in sales, while its PMO-based RNA therapies (EXONDYS 51, VYONDYS 53, AMONDYS 45) contributed $966 million. The company is the first and only company to commercialize an approved gene therapy for DMD.

Global Presence

Headquartered in Cambridge, Massachusetts, Sarepta markets its products primarily in the United States and has expanded into Japan and select European markets through its Roche partnership. Following a strategic restructuring in 2025 that included a 36% workforce reduction, the company maintains a focused organization of 835 employees. Cash reserves exceeded $950 million at year-end 2025, providing substantial runway for continued innovation.

Key Strengths

Sarepta's unique dual-platform approach combining AAV gene therapy and PMO antisense technology creates multiple avenues for DMD treatment. Its deep understanding of neuromuscular disease biology, strong regulatory relationships enabling rapid label expansion, and Roche partnership for ex-US commercialization position the company for continued leadership. Despite safety challenges, Sarepta's position as the only approved DMD gene therapy provider creates significant market power.

VerityRank Score

Sarepta Therapeutics achieves a VerityRank Score of 92/100, reflecting its pioneering role in neuromuscular gene therapy, strong commercial performance, and unique dual-platform technology advantage in rare disease treatment.